Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.74 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.74 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.74 |
| ▸ | PRKDC | P78527 | 2/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | SRC | P12931 | 1/20 | 0.74 |
| ▸ | MTOR | P42345 | 1/20 | 0.74 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.57 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7913656 | 0.92 | PIK3CD (0.76) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL7909458 | 0.91 | PIK3CD (0.76) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL12108114 | 0.88 | PIK3CD (0.79) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL29381345 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL31326456 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL1952680 | 0.85 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL18230918 | 0.85 | PIK3CD (0.76) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL7918993 | 0.85 | PIK3CD (0.89) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL12109895 | 0.84 | PIK3CD (0.78) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC | |
| SCHEMBL18230900 | 0.83 | PIK3CD (0.72) | PIK3CDPIK3CBPIK3CGPIK3CAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111153905-A | PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors | 理森制药股份公司 | 2020-05-15 | — | — | CN | claimed |
| CN-111153905-A | PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors | 理森制药股份公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-105431437-B | PI3K protein kinase inhibitors, in particular delta inhibitors and/or gamma inhibitors | 理森制药股份公司 | 2020-03-10 | — | — | CN | disclosed |
| US-9493467-B2 | PI3 kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493467-B2 | PI3 kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140288096-A1 | P13 KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288096-A1 | P13 KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-25 | — | — | US | disclosed |
| US-20110269779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010059593-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | INTELLIKINE, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20090270426-A1 | P13 Kinase Antagonists | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270426-A1 | P13 Kinase Antagonists | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | US | disclosed |
| US-20080032960-A1 | PI3 kinase antagonists | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080032960-A1 | PI3 kinase antagonists | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270426-A1 | P13 Kinase Antagonists | AKT3, PRKD3, CDK13 | PIK3CD 28/4885PIK3CB 17/4885PIK3CG 45/4885 |
| US-20140288096-A1 | P13 KINASE ANTAGONISTS | AKT3, PRKD3, CDK13 | PIK3CD 28/4885PIK3CB 17/4885PIK3CG 45/4885 |
| US-20110269779-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF OPHTHALMIC CONDITIONS | MTOR, PIK3C2B, PRKCH | PIK3CD 32/4885PIK3CB 9/4885PIK3CG 39/4885 |
| US-20080032960-A1 | PI3 kinase antagonists | PIK3CA, PIK3C2B, PIK3R5 | PIK3CD 8/4885PIK3CB 9/4885PIK3CG 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.